prostatespecif membrane antigen psa express high level align prostate cell like import therapeutic target treatment carcinoma current immunotherapi approach include peptide cell vector dramas vaccine well passive administer psmaspecif monoclonal antibody mab convent number list practice limit include product cost require frequent dose due short serum halflif report describe novel strategy antibodybas until synthetic dna plasmid encode human electroporationenhanc intramuscular inject dnaencod dab plasmid mouse led function durable antipsma antibody product vivo control tumor growth prolong survive mouse model media antibodydepend cellular cytotox acc effect aid nk studi approach disease conduit warrant 